The phase IV trial will enrol 1,004 chronic kidney disease (CKD) patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anaemia, the company said in a regulatory filing.
The phase IV trial will enrol 1,004 chronic kidney disease (CKD) patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anaemia, the company said in a regulatory filing.